Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ENTROPY NEURODYNAMICS LIMITED Director's Dealing 2024

May 5, 2024

64855_rns_2024-05-05_e49c41b3-cdbd-41dd-8de8-43d0d3cd8082.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.

Name of entity Tryptamine Therapeutics Limited (formerly Exopharm Limited)
ABN 78 163 765 991

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Chris Ntoumenopoulos
Date of appointment 1 May 2024

Part 1 - Director’s relevant interests in securities of which the director is the registered holder In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

Nil

  • See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interestNote: Provide details of the circumstances givingrise to the relevant interest.Sobol Capital Pty Ltd ATF Sobol CapitalTrust (Sole Director)Christopher Ntoumenopoulos & LeoNtoumenopoulos ATF TheNtoumenopoulos superannuation fund Number & class of Securities5,000,000 – Ordinary Fully Paid Shares18,903,780 – Options @ $0.027 Exp 3 years from thedate of Reinstatement (escrowed for 24 months fromthe date of official quotation)2,892,8000 – Options @ $0.0531 Exp 5 years from thedate of Reinstatement (escrowed for 24 months fromthe date of official quotation)1,250,000 – Ordinary Fully Paid Shares

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Nbe Nbe ote: In the case of a company, interests which come within paragrdisclosed in this part. ote: In the case of a company, interests which come within paragrdisclosed in this part. aph (ii) of the definitio of notifiable interest of a director should of a director should
Detail of contract N/A
Nature of interest N/A
Name of registered holder(if issued securities) N/A
No. and class of securities to whichinterest relates N/A
  • See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002